0000950170-24-042617.txt : 20240408 0000950170-24-042617.hdr.sgml : 20240408 20240408161555 ACCESSION NUMBER: 0000950170-24-042617 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240403 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 FILED AS OF DATE: 20240408 DATE AS OF CHANGE: 20240408 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Telesis Bio Inc. CENTRAL INDEX KEY: 0001850079 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 451216839 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40497 FILM NUMBER: 24829760 BUSINESS ADDRESS: STREET 1: 10431 WATERIDGE CIRCLE STREET 2: SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-228-4115 MAIL ADDRESS: STREET 1: 10431 WATERIDGE CIRCLE STREET 2: SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Codex DNA, Inc. DATE OF NAME CHANGE: 20210309 8-K 1 tbio-20240403.htm 8-K 8-K
false0001850079Telesis Bio Inc.00018500792024-04-032024-04-03

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 03, 2024

 

 

TELESIS BIO INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40497

45-1216839

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

10431 Wateridge Circle

Suite 150

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 228-4115

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

TBIO

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On April 3, 2024, Telesis Bio Inc. (the Company) received a letter (the Letter) from the Listing Qualifications Department (the Staff) of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that, based upon the Company's annual report on Form 10-K which was filed with the Securities and Exchange Commission (SEC) on March 29, 2024, the Company is not in compliance with the minimum stockholder’s equity requirement for continued listing set forth in Nasdaq Listing Rule 5450(b)(1)(A), which requires companies listed on the Nasdaq Global Select Market to maintain a minimum of $10,000,000 in stockholders' equity for continued listing (the Stockholders’ Equity Requirement).

The Letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on The Nasdaq Global Select market under the symbol “TBIO” at this time.

In accordance with Nasdaq Listing Rule 5810(c)(2), the Company has been provided a period of 45 calendar days, or until Monday, May 20, 2024, to submit a plan to regain compliance (the Compliance Plan). If the Compliance Plan is acceptable to the Staff, of which there can be no assurance, the Staff may grant an extension of up to 180 calendar days from the date of the Letter, or until September 30, 2024, to evidence compliance. If the Staff does not accept the Compliance Plan, the Company will have the opportunity to appeal the Staff’s determination to a Nasdaq Hearings Panel.

The Company intends to submit the Compliance Plan on or before May 20, 2024. However, there can be no assurance that the Company will be able to regain compliance with the Stockholders’ Equity Requirement or will otherwise be in compliance with the Nasdaq Listing Rules.

5.08 Shareholder Director Nominations

On April 8, 2024, the Board of Directors (the Board) of the Company determined that the Company’s 2024 Annual Meeting of Shareholders (the Annual Meeting) will be held at 8:00 a.m. Pacific Time on Monday, May 1, 2024 in virtual format. The Board also set April 8, 2024 as the record date for determining shareholders entitled to receive notice of, and vote at, the Annual Meeting.

Because the date of the Annual Meeting is more than 25 days prior to the anniversary date of the Company’s 2023 Annual Meeting of Shareholders, the Company is hereby providing notice of the revised deadlines for shareholder proposals via this Form 8-K. In accordance with the rules of the SEC and the Company’s bylaws, any shareholder proposal intended to be considered for inclusion in the Company’s proxy materials for the Annual Meeting must be received by the Corporate Secretary at the Company’s principal executive offices at 10431 Wateridge Circle, Suite 150, San Diego, California 92121 on or before the close of business on April 18, 2024. In addition to complying with this deadline, shareholder proposals intended to be considered for inclusion in the Company’s proxy materials for the Annual Meeting must also comply with the Company’s bylaws and all applicable rules and regulations promulgated by the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

In addition, any shareholder who intends to submit a proposal regarding a director nomination or who intends to submit a proposal regarding any other matter of business at the Annual Meeting and does not desire to have the proposal included in the Company’s proxy materials for the Annual Meeting, and any shareholder who intends to solicit proxies in support of such shareholder’s director nominees pursuant to the SEC’s “universal proxy” rules under SEC Rule 14a-19, must ensure that notice of any such nomination or proposal (including certain additional information specified in the Company’s bylaws) is received by the Corporate Secretary at the Company’s principal executive offices on or before the close of business on April 18, 2024.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Telesis Bio Inc.

 

 

 

 

Date:

April 8, 2024

By:

/s/ Todd R. Nelson

 

 

 

Todd R. Nelson
Chief Executive Officer

 

 EX-101.SCH 2 tbio-20240403.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document And Entity Information
Apr. 03, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 03, 2024
Entity Registrant Name Telesis Bio Inc.
Entity Central Index Key 0001850079
Entity Emerging Growth Company true
Entity File Number 001-40497
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-1216839
Entity Address, Address Line One 10431 Wateridge Circle
Entity Address, Address Line Two Suite 150
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 228-4115
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol TBIO
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G7&BN"^)]NK+NY *W3"W\RQ+50/>I"MJ(-.)_#1EZA$VY8<1(86> MY4)88TS<;_3\1C0>09:'[L#TA(XA+@W#"CTN*+N@U6/@24DM0H#E>QV3N7TR@ZN M6>1>9!CG*(.XLH/P4:V%&@/8-SF0!)?DJG547>EYIM[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E% M9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ ^H&(6&60>9(9 0 SP, !, !;0V]N M=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z3 M9UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A M.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+, M:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5C ME>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68* MR,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/ M^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " #Z@8A8!T%- M8H$ "Q $ @ $ 9&]C4')O<',O87!P+GAM;%!+ M 0(4 Q0 ( /J!B%A!4]B*[P "L" 1 " :\ !D M;V-0&UL4$L! A0#% M @ ^H&(6*D*T%*L! @!( !@ ("!#@@ 'AL+W=O&UL4$L! A0#% @ ^H&( M6)>*NQS $P( L ( !S \ %]R96QS+RYR96QS4$L! M A0#% @ ^H&(6#JJHN= 0 / ( \ ( !M1 'AL M+W=O7!E&UL4$L%!@ ) D /@( %$4 $! end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - tbio-20240403.htm 8 tbio-20240403.htm tbio-20240403.xsd http://xbrl.sec.gov/dei/2023 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tbio-20240403.htm": { "nsprefix": "tbio", "nsuri": "http://telesisbio.com/20240403", "dts": { "inline": { "local": [ "tbio-20240403.htm" ] }, "schema": { "local": [ "tbio-20240403.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_6122b2d7-1e18-48e9-bd32-770ab487053e", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tbio-20240403.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_6122b2d7-1e18-48e9-bd32-770ab487053e", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tbio-20240403.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://telesisbio.com/20240403/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-24-042617-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-042617-xbrl.zip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tbio-20240403_htm.xml IDEA: XBRL DOCUMENT 0001850079 2024-04-03 2024-04-03 false 0001850079 Telesis Bio Inc. 8-K 2024-04-03 DE 001-40497 45-1216839 10431 Wateridge Circle Suite 150 San Diego CA 92121 (858) 228-4115 N/A false false false false Common Stock, $0.0001 par value per share TBIO NASDAQ true false